 Becton Dickinson Co. reported Thursday fiscal second-quarter profit and sales that rose above expectations, boosted by 480 million in COVID-19 testing sales, and announced plans to separate its Diabetes Care business into an independent publicly traded company. The medical technology companys stock was still inactive in premarket trading. 